null

Brentuximab (Anti-CD30) Biosimilar Antibody

SKU:
HDBS0017
Product Type:
Biosimilar Antibody
Antibody Type:
Monoclonal Antibody
Protein:
CD30
Reactivity:
Human
Host Species:
Humanized
Isotype:
IgG1
$448
Frequently bought together:

Description

system_update_altDatasheet

Brentuximab (Anti-CD30) Biosimilar Antibody (HDBS0017)

The Anti-CD30 Brentuximab Vedotin Biosimilar Monoclonal Antibody (HDBS0017) is a cutting-edge tool for researchers studying CD30, a cell surface molecule highly expressed in Hodgkin's lymphoma and other lymphoproliferative disorders. This monoclonal antibody, developed using innovative biosimilar technology, specifically targets the CD30 protein and is validated for use in various immunohistochemistry applications.CD30, a member of the tumor necrosis factor receptor superfamily, is a key player in the pathogenesis of certain lymphomas and autoimmune diseases. The Anti-CD30 Brentuximab Vedotin Biosimilar Monoclonal Antibody provides researchers with a reliable tool for detecting and studying CD30 expression in cancer cells, aiding in the development of targeted therapies for lymphoma and other CD30-related diseases.

Whether you are investigating the role of CD30 in lymphoma pathogenesis or exploring novel treatment strategies, the Anti-CD30 Brentuximab Vedotin Biosimilar Monoclonal Antibody is an invaluable resource for your research needs. Its high specificity and sensitivity make it an essential tool for advancing our understanding of CD30 biology and developing personalized treatments for CD30-positive malignancies.